Inogen Inc (NASDAQ:INGN) Director Loren L. Mcfarland sold 2,125 shares of Inogen stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $181.44, for a total transaction of $385,560.00. Following the sale, the director now owns 3,114 shares in the company, valued at $565,004.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of NASDAQ INGN opened at $172.60 on Wednesday. Inogen Inc has a 1-year low of $83.26 and a 1-year high of $189.76. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of 131.76, a P/E/G ratio of 4.48 and a beta of 1.01.
Inogen (NASDAQ:INGN) last announced its earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.19. Inogen had a net margin of 9.36% and a return on equity of 14.81%. The company had revenue of $79.05 million during the quarter, compared to the consensus estimate of $63.86 million. During the same period in the previous year, the firm posted $0.27 earnings per share. The company’s revenue was up 50.6% on a year-over-year basis. sell-side analysts anticipate that Inogen Inc will post 1.76 EPS for the current year.
Several equities analysts recently issued reports on the stock. JPMorgan Chase lifted their price target on shares of Inogen from $150.00 to $180.00 and gave the company an “overweight” rating in a report on Tuesday, May 1st. Leerink Swann reissued an “outperform” rating and set a $170.00 price target (up from $150.00) on shares of Inogen in a report on Tuesday, May 1st. ValuEngine raised shares of Inogen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Tuesday, February 13th. Finally, BidaskClub raised shares of Inogen from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. One analyst has rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company. Inogen presently has an average rating of “Buy” and an average price target of $178.00.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.